Dose: Initially 375mg twice daily, increased if necessary after 2-4 weeks to 500mg twice daily Please note, in practice, 375mg twice daily is often used as a maintenance dose.
Higher doses may lead to QT prolongation (exercise caution with doses greater than 500mg twice daily)
Prescribing Notes
Ranolazine is indicated for treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies
Ranolazine inhibits myocardial late sodium current (hence reduces calcium influx) but does not affect heart rate or BP, thus may be particularly useful in patients with low BP and/or low heart rate
Caution
Caution in patients with body weight <60kg or borderline renal function (avoid if eGFR less than 30mL/minute/1.73m2)
Ranolazine is largely metabolised by the CYP3A4 system thus there is a potential for serious drug interactions, especially at higher doses (see BNF)
